Understanding the risk factors and the connection semaglutide may have with this condition is critical for your health management plan
Role of Incretins and DPP-4 in Glucose Regulation The functions and abundance of DPP-4 in the body have already been discussed in the above section
Research has shown that Wegovy (semaglutide 2.4 mg) can lead to a weight loss of around 16% of your body weight, or 16-17kg, after 68 weeks
A significant sign that the injections are working is a reduction in symptoms of vitamin B12 deficiency, such as weakness, rapid heart rate, easy bruising or bleeding, and pale skin
The bottom line Newer GLP-1-based drugs can lead to powerful benefits for blood sugar, weight, and heart health, but nausea can make treatment unpleasant especially during the first few weeks of treatment or shortly after increasing the dose